Ephenidine (N-ethyl-1,2-diphenylethylamine, NEDPA) is a synthetic dissociative of the diarylethylamine class — structurally and experientially distinct from the arylcyclohexylamine dissociatives (ketamine, PCP, MXE) that dominate the category. It is the N-ethyl analog of diphenidine, differing by a single carbon on the nitrogen chain, and like its parent compound it produces a style of dissociation that community members consistently describe as "dreamy," "cinematic," and qualitatively foreign compared to the sharp, geometric detachment of ketamine or the analytical coldness of PCP analogs. Where ketamine carves the world into angular abstractions, ephenidine dissolves it into something that feels like inhabiting a half-remembered film.
Pharmacologically, ephenidine is a potent NMDA receptor antagonist with a documented binding affinity of Ki = 66.4 nM — actually substantially more potent than ketamine at this receptor, though in vitro binding does not translate directly to human dose equivalence due to differences in CNS penetration, metabolism, and protein binding. It also shows affinity for the dopamine transporter (Ki = 379 nM), norepinephrine transporter (Ki = 841 nM), and sigma receptors (σ1 = 629 nM, σ2 = 722 nM). This polypharmacology distinguishes it from arylcyclohexylamines and likely accounts for its unusual experiential character. The diarylethylamine scaffold — two phenyl rings flanking an ethylamine chain, no cyclohexyl ring — represents a genuinely different structural approach to NMDA antagonism.
The experience lasts 6 to 8 hours orally, with a slow, deceptive onset that has caught many users off guard. Full effects may not manifest until 90 minutes or more, making premature redosing a well-documented hazard. The dissociation unfolds gradually into a deeply immersive, narrative-rich state that is less spatial and geometric than ketamine and more populated by scenes, figures, and emotional textures. Community reports consistently note that the diarylethylamine experience has a "foreign" quality — it does not map easily onto the ketamine/PCP/MXE framework and requires its own mental vocabulary.
Ephenidine appeared in the research chemical market in the mid-2010s alongside diphenidine and methoxphenidine (MXP), part of a brief wave of diarylethylamine exploration. Community engagement was active but more limited than with arylcyclohexylamines. Comparative reports — including systematic vaporization experiments documented on Reddit and Bluelight — generally concluded that diphenidine was preferred over ephenidine for subjective quality of experience. Legally, ephenidine occupies an unusual position: it is a structural isomer of lefetamine (SPA), a Schedule IV controlled substance in the United States, though the isomer clause has rarely if ever been invoked for prosecution. It is explicitly controlled in Canada (Schedule I as an MT-45 analog), Germany, Sweden, Switzerland, Turkey, and the United Kingdom.
Safety at a Glance
High Risk- Wait Before Redosing — The Most Important Rule
- Start Low, Especially Without Diarylethylamine Experience
- Toxicity: Formal Toxicity Data Ephenidine's formal toxicity profile is limited. No systematic human or animal toxicological stu...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Recognizing a Dangerous Situation Ephenidine overdose can present as either primarily physical or...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 7 hrsHow It Feels
The first hour passes with an almost deceptive mildness — a faint tingling in the hands, a subtle shift in the acoustics of the room, a sense that your thoughts have begun to move through a slightly thicker medium. You might wonder if the compound is active at all. Then, somewhere around the ninety-minute mark, the dissociation arrives in earnest, unfolding like a landscape revealed by receding fog: suddenly there is depth where there was none, and the room you thought you knew has become somewhere else entirely.
The come-up is dreamy in the most literal sense — reality takes on the logic of a dream, where transitions between thoughts and scenes happen without the usual connective tissue. One moment you are considering the texture of the carpet; the next, you are somehow contemplating a memory from childhood, and the two feel equally present, equally real. The body grows numb and distant, a warm heaviness that encourages stillness. Sound becomes muffled and layered, as though multiple rooms are overlapping in the same space. There is a confusion to this, but it is a soft confusion, more bewildering than distressing — the confusion of waking up in an unfamiliar hotel room rather than the confusion of being lost.
At the peak, the dreamy quality intensifies into something approaching genuine derealization. The world is present but unconvincing, like a stage set viewed from too close — you can see the seams, the places where surfaces meet at angles that do not quite make sense. Closed-eye space is rich and narrative: not the geometric abstractions of the arylcyclohexylamines but something more cinematic, populated by scenes and figures that arrive with the emotional weight of memories even when they are entirely invented. Music is extraordinary, acquiring a depth and emotional complexity that feels almost overwhelming. There is a gentleness to the peak that distinguishes it from the sharper dissociatives — you are not being disassembled so much as being slowly relocated to somewhere adjacent to reality.
The duration is long — six to eight hours — and the descent is marked by waves of lucidity alternating with renewed confusion. You may think you are back to baseline only to find, ten minutes later, that the room has gone dreamy again. Sleep eventually comes but may be delayed by the compound's mild stimulant undertone. The morning after is surprisingly clear, with a faint residual dreaminess that fades by midday, leaving behind the sense of having spent the night in a place that was almost, but not quite, real.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(16)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Cough suppression— A decreased desire and need to cough, medically known as antitussive action, which can also allow in...
- Decreased libido— Decreased libido is a diminished interest in and desire for sexual activity, commonly caused by subs...
- Gait alteration— Gait alteration is a noticeable change in the way a person walks and moves through their environment...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(12)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(24)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Ego replacement— Ego replacement is the experience of one's usual personality and sense of self being completely over...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Auditory(5)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
- Auditory suppression— A dampening of auditory perception in which sounds become muffled, distant, and reduced in both volu...
Multi-sensory(2)
- Memory replays— Memory replays are vivid, multisensory re-experiences of past events that go far beyond normal recal...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
Pharmacology
NMDA Receptor Antagonism
Ephenidine is a non-competitive NMDA receptor antagonist with a binding affinity of Ki = 66.4 nM, established by Bhatt et al. (2017) and Wallach et al. (2016). This is substantially more potent than commonly cited values for ketamine at the NMDA receptor (Ki ≈ 659 nM at the PCP binding site), placing ephenidine in the same order of magnitude as potent arylcyclohexylamines like 3-MeO-PCP and 3-MeO-PCE. However, the relationship between in vitro binding affinity and human psychoactive dose is mediated by pharmacokinetic factors — CNS penetration, hepatic metabolism, plasma protein binding, and volume of distribution all intervene between a Ki value and what someone actually feels. Ephenidine's oral doses (70-150 mg) are considerably higher than what its NMDA affinity alone would predict, suggesting pharmacokinetic barriers that reduce its effective CNS concentration relative to its receptor potency.
The NMDA antagonism produces the characteristic dissociative syndrome: disruption of thalamocortical sensory gating, progressive disconnection between sensory input and conscious processing, analgesia, and at sufficient doses, complete dissociative anesthesia. The subjective character of ephenidine's dissociation is qualitatively different from arylcyclohexylamines, suggesting that the exact binding kinetics — how the molecule enters and exits the NMDA channel, its dwell time, its state-dependent properties — differ meaningfully between structural classes.
Monoamine Transporter Activity
Ephenidine shows meaningful affinity for the dopamine transporter (Ki = 379 nM) and norepinephrine transporter (Ki = 841 nM). These values are moderate but pharmacologically relevant — the dopamine transporter affinity is in the range where reuptake inhibition would contribute to subjective effects. This monoamine activity likely contributes to the mild stimulant undertone that persists through the experience and can delay sleep after the dissociative effects have resolved. Unlike 3-MeO-PCP or 3-MeO-PCE, ephenidine's monoamine reuptake inhibition does not dominate the experience, but it colors it.
Sigma Receptor Binding
Sigma-1 (Ki = 629 nM) and sigma-2 (Ki = 722 nM) receptor binding is present and may contribute to the hallucinogenic and emotional qualities of the experience. Sigma receptor activation is implicated in the dreamy, derealized quality that diarylethylamines produce more prominently than arylcyclohexylamines.
Diarylethylamine Class Properties
The structural distinction from arylcyclohexylamines is fundamental: ephenidine lacks the cyclohexyl ring entirely, instead featuring two phenyl rings flanking an ethylamine chain. This architecture produces a different receptor selectivity profile and different pharmacokinetics. The N-ethyl substitution compared to diphenidine's N-methyl group increases lipophilicity, alters hepatic metabolism (producing different metabolite profiles via CYP2D6 and CYP3A4), and may change CNS penetration kinetics. Wink et al. (2014) characterized the metabolic pathways, identifying N-deethylation, hydroxylation, and methylation as primary routes. Community experience consistently reports that the methyl-to-ethyl change produces a less desirable experiential profile than diphenidine, though significant individual variability exists.
Pharmacokinetics
Oral onset is slow: 45-90 minutes to initial effects, with full manifestation sometimes requiring 120 minutes. This slow onset is a major harm reduction concern, as it frequently leads to premature redosing. Duration is 6-8 hours with residual effects persisting longer. Vaporization produces dramatically faster onset (minutes) but with significantly reduced dose requirements — community reports suggest approximately 20% of the oral dose is needed, indicating much higher bioavailability via this route. Vaporization at excessive temperatures raises concerns about pyrolysis products and potential carcinogenicity.
Detection Methods
Standard Drug Panel Inclusion
Ephenidine (N-ethyl-1,2-diphenylethylamine, NEDPA) is NOT included on standard drug screening panels. It does not cross-react with PCP, ketamine, or any other immunoassay class. The diarylethylamine structure prevents detection by standard screening methods. Standard 5-panel, 10-panel, and extended panels will return negative results.
Urine Detection
Ephenidine is detectable in urine for approximately 2 to 5 days after a single dose. The compound undergoes hepatic metabolism including N-deethylation, hydroxylation, and methylation. LC-MS/MS methods specifically targeting ephenidine and its metabolites are required. The metabolic profile has been partially characterized through in vitro studies and case report analyses.
Blood and Serum Detection
Blood detection windows are approximately 1 to 3 days. Pharmacokinetic data is limited. The relatively long duration of action (3 to 6 hours) suggests moderate metabolic stability and a half-life in the range of several hours.
Hair Follicle Detection
Hair analysis is feasible with LC-MS/MS methods but has not been widely validated for ephenidine specifically.
Confirmatory Methods
LC-MS/MS is required for definitive identification. GC-MS with electron impact ionization can also identify the compound. Reference standards are available from specialized forensic chemistry suppliers.
Reagent Testing
Reagent testing profiles for ephenidine are poorly documented. Standard reagents may produce nonspecific or absent color changes. Fentanyl test strips should be used on any product obtained from unregulated sources.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Structural Origins
Ephenidine emerged from the systematic exploration of diarylethylamine structure-activity relationships — the same chemical space that produced diphenidine and methoxphenidine (MXP). The diarylethylamine scaffold was known from the pharmaceutical compound lefetamine (SPA), an analgesic with opioid and NMDA antagonist properties first described in the 1950s and placed in Schedule IV of the UN Convention on Psychotropic Substances. Ephenidine is a structural isomer of lefetamine, sharing the same molecular formula but with a different arrangement of atoms — a fact that creates legal ambiguity in jurisdictions where isomer clauses exist.
Research Chemical Market Appearance
Ephenidine appeared in European and international research chemical markets in the mid-2010s, offered alongside diphenidine and methoxphenidine as novel dissociatives structurally distinct from the arylcyclohexylamine analogs that dominated the market. Vendor listings typically described it as a research chemical "not for human consumption," though the compounds were clearly marketed to the psychonautic community. Community engagement was active but less extensive than with arylcyclohexylamines — the diarylethylamine experience was divisive, with some users appreciating the dreamy, cinematic quality and others finding it uncomfortably foreign.
Community Pharmacological Research
The most valuable documentation of ephenidine came from systematic community comparison reports. A notable Reddit account described vaporizing both ephenidine and diphenidine, concluding that "neither was anywhere near as good as vaporizing diphenidine" — contributing to the consensus that the N-ethyl substitution produced a less desirable experience than diphenidine's N-methyl group. Bluelight's "Big & Dandy Ephenidine Thread" served as the primary community knowledge repository. These reports constituted a decentralized SAR study, documenting how the methyl-to-ethyl change on the nitrogen affected onset, duration, subjective quality, and side effect profile.
Academic Characterization
Wallach et al. (2016) published the definitive pharmacological characterization in PLoS One, establishing binding affinities for ephenidine, diphenidine, and methoxphenidine across NMDA, monoamine transporter, and sigma receptor targets. Bhatt et al. (2017) published in Neuropharmacology confirming ephenidine's NMDA antagonist properties. Wink et al. (2014) characterized the metabolic pathways. Eiden et al. (2018) documented clinical complications reported to the French Addictovigilance Network, providing the first formal adverse event data.
Regulatory Response
Canada classified ephenidine as Schedule I in March 2016 under MT-45 analog provisions. Sweden scheduled it in August 2015 following a public health agency recommendation. Germany controlled it under the New Psychoactive Substances Act (NpSG). Switzerland named it specifically under Verzeichnis E. The United Kingdom's Psychoactive Substances Act (May 2016) effectively banned its sale. In the United States, ephenidine's status remains ambiguous — as a possible positional isomer of lefetamine (Schedule IV), it could theoretically be prosecuted under isomer clauses, but this has never been tested.
Harm Reduction
Wait Before Redosing — The Most Important Rule
Ephenidine has a slow, deceptive onset that has caught experienced dissociative users off guard. Full effects may not manifest for 90-120 minutes after oral ingestion. The number one source of adverse experiences with this compound is redosing during what feels like an inactive waiting period, then having both doses hit simultaneously. Commit to waiting a minimum of two full hours before making any assessment of whether the initial dose was sufficient. Pre-measure your dose and put the rest away.
Start Low, Especially Without Diarylethylamine Experience
If you have not used diarylethylamines before, your arylcyclohexylamine experience does not fully transfer. The subjective character is different enough that your calibrated sense of "how dissociated am I" may not apply. Start with 50-70 mg oral, assess the full experience, and adjust from there in future sessions. Experienced users typically work in the 80-120 mg range oral, with 150 mg+ being heavy.
Create a Safe Physical Environment
At dissociative doses, motor control is significantly impaired. Ephenidine's dreamy quality can lead to disorientation about where you are and what surfaces are safe to walk on. Set up your space before onset: remove tripping hazards, have water within reach, ensure you are not near water hazards (pools, bathtubs, open water). A sober companion is strongly recommended for doses above 100 mg.
Route-Specific Considerations
Community exploration of vaporization has documented that this route requires approximately 20% of the oral dose, with dramatically faster onset. If you choose to explore non-oral routes, recognize that published dose guidelines are typically oral-specific. Vaporization at excessive temperatures raises concerns about pyrolytic degradation products and potential carcinogenicity — this is not a theoretical concern.
Dangerous Combinations
- CNS depressants (alcohol, opioids, benzodiazepines, GHB) — The leading cause of dissociative-associated fatalities across all compounds. Synergistic respiratory depression and aspiration risk. The long duration of ephenidine means overlap with other substances is likely if they are consumed at any point during the experience
- Stimulants — Increased cardiovascular strain and elevated risk of adverse psychological reactions
- MAOIs — Potentially dangerous given ephenidine's monoamine transporter activity
- Other dissociatives — Unpredictable potentiation across different receptor profiles
Benzodiazepine Safety Net
Keep a benzodiazepine (diazepam 10 mg) available for overwhelming experiences. This is standard dissociative harm reduction. Given ephenidine's long duration, having this option available provides genuine psychological reassurance even if it is never used.
Reagent Test Your Material
Ephenidine's reagent profile is poorly documented, which limits the utility of colorimetric testing. Fentanyl test strips are essential for any material obtained from unregulated sources. Where available, professional drug checking services provide the most reliable identification.
Toxicity & Safety
Formal Toxicity Data
Ephenidine's formal toxicity profile is limited. No systematic human or animal toxicological studies have been published. The acute toxic dose is unknown. Available safety data comes from case reports (Eiden et al. 2018, documenting complications in the French Addictovigilance Network), community experience reports, and extrapolation from the diarylethylamine class and NMDA antagonist pharmacology.
Acute Toxicity
NMDA antagonism at high doses carries the risk of respiratory depression, particularly when combined with other CNS depressants. The significant motor impairment at dissociative doses creates fall and injury risk. The long duration (6-8 hours) means the window of impairment — and the window of vulnerability to environmental hazards — is extended.
Psychological Risks
Ephenidine's dissociation is described by community members as having a "foreign" or unusual quality compared to arylcyclohexylamines. This unfamiliar character can manifest as distressing or disturbing experiences at higher doses, particularly in users whose expectations are calibrated to ketamine or similar compounds. Derealization can be intense and prolonged. The dreamy, narrative quality of the experience means that psychologically difficult content — disturbing scenarios, emotional memories — arrives with the full emotional weight of lived experience rather than the abstract detachment of more typical dissociatives.
Cardiovascular Effects
Dopamine and norepinephrine transporter activity (Ki = 379 nM and 841 nM respectively) means ephenidine has mild sympathomimetic properties. Elevated heart rate is reported. Significant cardiovascular risk at standard doses in healthy individuals is unlikely, but pre-existing cardiovascular conditions represent a contraindication.
Pyrolysis Concerns
Community exploration of vaporization has raised concerns about the thermal stability of the diarylethylamine molecule. Excessive heat during vaporization may produce pyrolysis products with unknown toxicity, including potentially carcinogenic compounds. This is not a well-characterized risk but represents a genuine concern specific to non-oral routes.
Drug Interactions
CNS depressants (alcohol, opioids, benzodiazepines, GHB) increase respiratory depression and aspiration risk — the combination of depressed protective reflexes with the nausea sometimes produced by ephenidine creates a specific aspiration hazard. The standard dissociative interaction warnings apply across the board. Monoamine transporter activity means MAOI combinations carry serotonin syndrome risk.
Comparison to Diphenidine
Available community reports do not suggest dramatically different toxicity profiles between ephenidine and diphenidine, though the experiential character differs. Both compounds share diarylethylamine-class uncertainty regarding metabolite-specific toxicities and long-term effects of repeated exposure.
Addiction Potential
Moderately addictive with a meaningful potential for psychological dependence. Ephenidine's addiction risk profile is intermediate among dissociatives — less reinforcing than ketamine, 3-MeO-PCE, or 3-MeO-PCP, but carrying the same fundamental dissociative dependence mechanisms: escape from negative emotional states, the appeal of altered consciousness as relief from ordinary life, and the gradual normalization of a dissociated baseline. Tolerance develops with prolonged and repeated use, requiring escalating doses that increase both the risk of adverse effects and the depth of dependence. The half-tolerance reset period is approximately 3-7 days, with full baseline return in 1-2 weeks in the absence of further use. Cross-tolerance exists with all dissociatives — after ephenidine use, ketamine, PCP analogs, and other NMDA antagonists will produce reduced effects. Compulsive redosing within a session is documented, driven partly by the slow onset creating a window where the user feels nothing and is tempted to take more. Physical withdrawal is not well characterized but likely includes anxiety, insomnia, irritability, and cognitive fog consistent with dissociative cessation syndromes. The long duration of action provides some natural protection against the rapid redosing cycles that make ketamine particularly habit-forming, but the dreamy escapism of the diarylethylamine experience can become psychologically compelling for users seeking dissociation from distressing life circumstances.
Overdose Information
Recognizing a Dangerous Situation
Ephenidine overdose can present as either primarily physical or primarily psychological depending on dose and circumstances.
Physical warning signs requiring immediate medical attention: severe nystagmus with complete unresponsiveness, vomiting while unconscious (aspiration risk is the primary acute killer with dissociative overdoses), severely depressed or irregular breathing, seizures, extremely elevated heart rate or blood pressure, and cyanosis (blue-tinged lips or fingernails indicating inadequate oxygenation).
Psychological warning signs: complete dissociation from reality persisting beyond the expected 6-8 hour window, severe agitation or panic that cannot be managed with environmental changes and reassurance, catatonic unresponsiveness, or self-harm behavior.
Emergency Response
Place the person in the recovery position immediately — on their side, with the upper leg bent forward to prevent rolling, head tilted to allow fluids to drain from the mouth. This single intervention addresses the aspiration risk that accounts for most dissociative-related deaths. Monitor breathing continuously. Call emergency services if breathing becomes slow, shallow, or irregular; if the person cannot be roused by voice or physical stimulation; if vomiting occurs while unconscious; or if seizures occur.
Be honest with medical personnel about what was consumed. Ephenidine is obscure enough that clinicians will almost certainly be unfamiliar with it. Providing the compound name, noting that it is a diarylethylamine NMDA antagonist with a 6-8 hour duration, and stating the approximate dose and time of ingestion gives the medical team the information they need. There is no specific pharmacological antagonist for ephenidine — treatment is entirely supportive, focused on airway management, monitoring, and symptomatic care.
Why Ephenidine Overdoses Happen
The slow onset is the primary culprit. Users expecting effects within 30-45 minutes (as with ketamine or many other dissociatives) redose at 60 minutes when they feel nothing, then experience both doses simultaneously at the 90-120 minute mark. This pattern is documented repeatedly in community reports. The second common pathway is underestimating the dose conversion between routes — vaporization requires roughly 20% of the oral dose, and users transitioning from oral to vaporized administration without adjusting their dose can dramatically overshoot.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Ephenidine is illegal in some countries as a structural isomer of the banned opioid drug lefetamine.
Canada:** As of March 2016, MT-45 and its analogues, one of which being ephenidine, are Schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
Germany: Ephenidine is a controlled substance under the NpSG (New Psychoactive Substances Act) as a derivative of 2-Phenylethylamine.
Sweden:** Following a suggestion by Sweden's public health agency that ephenidine be classified as a hazardous substance on June 2015, ephenidine became a scheduled substance as of August 2015.
Switzerland:** Ephenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Ephenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Ephenidine is illegal to produce, supply, or import in the U.K. under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Ephenidine could possibly be considered a positional isomer of SPA (lefetamine), which is a Schedule IV drug. However, the isomer clauses within the legal text of the Schedules have rarely, if ever, been used for prosecution.
Responsible use
Research chemical
Dissociative
Diarylethylamine
Ephenidine (Wikipedia)
Ephenidine (Isomer Design)
Community
The Big & Dandy Ephenidine (N-ethyl-1,2-diphenylethylamine) Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Wink, Carina S. D., et al. “Lefetamine‐Derived Designer Drugs N‐Ethyl‐1,2‐Diphenylethylamine (NEDPA) and N‐Iso‐Propyl‐1,2‐Diphenylethylamine (NPDPA): Metabolism and Detectability in Rat Urine Using GC‐MS, LC‐MSn and LC‐HR‐MS/MS.” Drug Testing and Analysis, John Wiley & Sons, Ltd, 3 Mar. 2014, https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.1621.
“Toxicokinetics of Lefetamine and Derived Diphenylethylamine Designer Drugs-Contribution of Human Cytochrome P450 Isozymes to Their Main Phase I Metabolic Steps.” Toxicology Letters, Elsevier, 11 Aug. 2015, https://www.sciencedirect.com/science/article/pii/S0378427415300333.
“Ephenidine: A New Psychoactive Agent with Ketamine-like NMDA Receptor Antagonist Properties.” Neuropharmacology, Pergamon, 9 Aug. 2016, https://www.sciencedirect.com/science/article/pii/S0028390816303392.
Eiden, Céline, et al. “Ephenidine, Diphenidine, and Methoxphenidine Complications Reported to the French Addictovigilance Network.” Fundamental & Clinical Pharmacology, John Wiley & Sons, Ltd (10.1111), 23 July 2018, https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12395.
Experience Reports (1)
Tips (8)
Combining Ephenidine with stimulants places extreme strain on the cardiovascular system. The opposing effects on heart rate and blood pressure can cause dangerous fluctuations and cardiac events.
Do not combine Ephenidine with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Test Ephenidine with appropriate reagent kits. Dissociative powders are frequently mislabeled or adulterated. A Mandelin reagent test helps distinguish between some common dissociatives. Always use fentanyl test strips as well.
Weigh your dose of Ephenidine with a milligram scale. Dissociative dose-response curves are steep. The difference between a pleasant floaty experience and complete dissociation from reality can be 50mg or less.
Ephenidine has a slow onset of 1-2 hours orally and effects can last 6-8 hours. Do not redose thinking it has not worked. The long duration means any miscalculation in dosing commits you to an extended experience.
Ephenidine has significant residual stimulation that can persist well after the dissociative effects fade. Users report being unable to sleep many hours after the experience ends, sometimes with chest tightness and body twitching. Plan for a long recovery window.
Community Discussions (1)
See Also
Similar by Effects
Same Class
References (4)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- PubChem: Ephenidine
PubChem compound page for Ephenidine (CID: 110821)
pubchem - Ephenidine - TripSit Factsheet
TripSit factsheet for Ephenidine
tripsit - Ephenidine - Wikipedia
Wikipedia article on Ephenidine
wikipedia